Covetrus, Inc.

CVETNASDAQHealthcare

$20.99

+$0.00(+0.00%)

Market Cap$0

P/E Ratio—

52W High$21.2

52W Low$13.39

Avg Volume1.2M

Open$20.93

Beta1.51

PE Ratio Market Cap Forecast

Covetrus, Inc. (CVET) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

cvet · pe ratio · data through Dec 31, 2021

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Covetrus, Inc. (CVET) measures how much investors pay for each dollar of the company's trailing earnings. CVET's current PE ratio of N/A is calculated by dividing its stock price of $20.99 by its TTM earnings per share of -$0.63.

N/A

P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2021-12-31

Forward P/E

N/A

—

EPS (TTM)

-$0.63

TTM · diluted EPS

PEG Ratio

-0.17

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Covetrus, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2015 – 2021 · Annual

PE Ratio (TTM)

5Y Avg 64.1x

EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 4 fiscal years · Front-end computed

Average

64.1x

4-yr mean

Median

67.9x

4-yr midpoint

Minimum

45.2x

Lowest year

Maximum

75.6x

Highest year

45.2x
MinQ1 · 25%67.9x
MedianQ3 · 75%75.6x
Max

Historically Low

At N/A, CVET's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.

0th percentileHigher than 0 of 4 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Medical - Distribution · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
Covetrus, Inc.You CVET	—	N/A	—	-$0.63
Amedisys, Inc. AMED	$3.3B	68.71x	—	$1.32
Chinook Therapeutics, Inc. KDNY	$2.7B	N/A	—	-$2.87
Longboard Pharmaceuticals, Inc. LBPH	$2.3B	N/A	—	-$2.39
MorphoSys AG MOR	$2.9B	N/A	—	-$1.38
Morphic Holding, Inc. MORF	$2.9B	N/A	—	-$3.59
Myovant Sciences Ltd. MYOV	$2.6B	N/A	—	-$2.22

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years

Fiscal Year End	PE Ratio	EPS (TTM)	YoY Change
2021-12-31Latest FY2021	—	$-0.63	—
2020-12-31 FY2020	—	$-0.16	—
2019-12-31 FY2019	—	$-9.52	—
2018-12-29 FY2018	45.21x	$0.91	-36.2%
2017-12-31 FY2017	70.86x	$0.58	+9.2%
2016-12-31 FY2016	64.87x	$0.63	-14.2%
2015-12-31 FY2015	75.59x	$0.54	—

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

PE Ratio = Stock Price ÷ EPS (TTM)

= $20.99 ÷ -$0.63 = N/A

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

CVET pe ratio · 6 questions

CVET's current PE ratio is N/A as of 2026-06-08, based on a stock price of $20.99 and TTM EPS of -$0.63. Data sourced from Financial Modeling Prep via CVET's SEC 10-K and 10-Q filings.

CVET PE ratioWhat is CVET PE ratioCurrent PE ratio of CVETCVET PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Covetrus, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08